Evolocumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1311 publications
Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.
Journal: American journal of therapeutics
Published: June 24, 2026
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
Journal: Journal of lipid research
Published: June 13, 2026
Drugs for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Comparison chart: Some non-statin lipid-lowering drugs.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Top studies of 2025 relevant to primary care: From the PEER team.
Journal: Canadian family physician Medecin de famille canadien
Published: May 13, 2026
Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is effective and safe in the treatment of hyperlipidemia in chronic kidney disease stage 3 - 4.
Journal: International journal of clinical pharmacology and therapeutics
Published: May 11, 2026
PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study.
Journal: European heart journal supplements : journal of the European Society of Cardiology
Published: May 08, 2026
Potential beneficial effect of treatment with PCSK9 inhibitors on vascular endothelial dysfunction: a systematic review and meta-analysis.
Journal: Expert review of clinical pharmacology
Published: May 06, 2026
Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.
Journal: JAMA network open
Published: May 05, 2026
Last Updated: 06/30/2026